What the Failure of Biogen’s Aducanumab Tells Us About Alzheimer’s — Risk Reduction is Still Our Best Weapon Today I serve as Neurotrack’s Head Writer. But three years ago, in a different professional incarnation, I had the privilege of sitting in a packed conference room with a bright, articulate representative from the pharmaceutical company Biogen […]
Read more
Patterns of behavioral change can vary from patient to patient, even within a diagnostic category. It is in this sense that some experts are calling for Alzheimer’s to be described as a spectrum disorder, rather than as a disease, with an easily identifiable set of symptoms.
Read more
Most people believe there’s nothing you can do to prevent Alzheimer’s disease, so they’re reluctant to discover the state of their cognitive health.
Read more
Facing this issue head-on doesn’t have to be a negative experience. We all have challenges to face and dealing with this one in a positive, constructive, optimistic way brings with it many benefits.
Read more